Skip to main content

Table 4 Selected CAR-T cell trials in relapsed or refractory mantle cell lymphoma

From: Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

  ZUMA-2 ZUMA-2 Transcend
  (KTE-X19) Update (Liso-Cel)
Patient n = 68   n = 34
Prior SCT 43%   40%
Prior BTKi 100%   87.5%
TP53 mutation 17%    22%
ORR 93% 92% 84%
CR 67% 67% 59%
Median DOR NR NR NR
PFS 61% 59.2% NR
OS 83% 67% NR
CRS, any 91% NA 50%
≥ 3 15% 15% 0%
Neurotoxicity, any 63% NA 28%
≥ 3 31% 31% 9%
Neutropenia ≥ 3 85% 85% 34%
Anemia ≥ 3 50% 53% 31%
Thrombocytopenia ≥ 3 51% 53% 34%
TLS ≥ 3 NA NA 3%
Grade 5 AE 3% 0 0
Reference [9] [42] [43]
  NEJM, 2020 ASH, 2020 ASH 2020, #118